{"entity":{"id":"evorpacept","kind":"drug","name":"Evorpacept","aka":["Evorpacept (ALX148)"],"tldr":"Evorpacept is an experimental immune checkpoint modulator from ALX Oncology in phase 3 trials for gastric & gastro-oesophageal junction cancer, HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.","summary":"Evorpacept (ALX148) is an immune checkpoint modulator developed by ALX Oncology. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05002127 (A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)), in gastric & gastro-oesophageal junction cancer, HR-positive / HER2-negative breast cancer and HER2-positive breast cancer. The largest, NCT05002127, plans to enrol 127 participants (actual) with primary completion was scheduled for 2024-05-24 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Evorpacept","url":"https://clinicaltrials.gov/search?intr=ALX148"},{"label":"Sponsor page","url":"https://www.alxoncology.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":["cd47-blockade"],"targets":[],"drugs":[],"companies":["alx-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":["aspen-06","nct04675294","nct04675333","nct07007559"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"ALX148","modality":"immune checkpoint modulator","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/evorpacept/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"cd47-blockade","kind":"technology","name":"CD47 and SIRP-alpha blockade","route":"/technologies/cd47-blockade/"}],"company":[{"id":"alx-oncology","kind":"company","name":"ALX Oncology","route":"/companies/alx-oncology/"}],"trial":[{"id":"aspen-06","kind":"trial","name":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)","route":"/trials/aspen-06/"},{"id":"nct07007559","kind":"trial","name":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer","route":"/trials/nct07007559/"},{"id":"nct04675333","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)","route":"/trials/nct04675333/"},{"id":"nct04675294","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)","route":"/trials/nct04675294/"},{"id":"nct05868226","kind":"trial","name":"PRE-ISPY Phase I/II Oncology Platform Program","route":"/trials/nct05868226/"}]}}